Zealand Pharma A/S Zealand Pharma A/S

Zealand Pharma A/S

ZEAL

Kedudukan dalam Saham #5442
Zealand Pharma A/S is a Danish biotechnology firm dedicated to the... Zealand Pharma A/S is a Danish biotechnology firm dedicated to the identification, progression, and market introduction of peptide-based therapeutics. The company concentrates its efforts on treatments for gastrointestinal and metabolic ailments, as well as other specialized conditions where current medical options are insufficient. Its commercialized product, Dasiglucagon, is an injectable solution provided in a pre-filled syringe or autoinjector, used to address severe hypoglycemia. Furthermore, Zealand Pharma is actively developing Dasiglucagon for inclusion in bi-hormone artificial pancreas systems that integrate both insulin and dasiglucagon. The compound Dasiglucagon is also undergoing late-stage (Phase III) clinical trials for congenital hyperinsulinism. Another significant asset in its development pipeline is glepaglutide, a long-acting GLP-2 analog, which is likewise in Phase III clinical studies for treating short bowel syndrome. Founded in 1998 and headquartered in Copenhagen, Denmark, Zealand Pharma A/S maintains strategic alliances with a range of partners, including Sanofi-Aventis Deutschland GmbH, Boehringer Ingelheim International GmbH, Alexion Pharmaceuticals, Inc., and Beta Bionics, Inc.
Harga Saham
$36.41
Disegerakkan terakhir: 2026-10-20
Modal Pasaran
$2.53B
Perubahan (1 hari)
3.76%
Perubahan (1 tahun)
-49.69%
Negara
DK
Perdagangan Zealand Pharma A/S (ZEAL)

Kategori

Healthcare
Hasil untuk Zealand Pharma A/S (ZEAL)
Hasil pada Oct 2026 TTM: 0
Menurut laporan kewangan terkini daripada Zealand Pharma A/S, hasil semasa syarikat (TTM) ialah 0. Pada tahun 2026, syarikat memperoleh hasil sebanyak 0 sama dengan hasil pada tahun 2026 iaitu 0. Hasil ialah jumlah pendapatan keseluruhan yang dijana oleh syarikat daripada jualan barangan atau perkhidmatan. Tidak seperti keuntungan, tiada perbelanjaan ditolak.
Sejarah hasil bagi Zealand Pharma A/S dari 2026 hingga 2026
Hasil pada akhir setiap tahun
Tahun Hasil Ubah
Tidak cukup data untuk tarikh yang disediakan.
Hasil untuk syarikat atau pesaing serupa
Syarikat Hasil Perbezaan Hasil Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL